نتایج جستجو برای: deferasirox
تعداد نتایج: 613 فیلتر نتایج به سال:
Malaventura C, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Comparison of effects of oral deferiprone and subcutaneous desfer-rioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Effects of chelation therapy on cardiac ...
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. Long-term hematological response in a patient with 5q-syndrome after suspension of lenalidomide therapy and further improvement with deferasirox therapy TO THE EDITOR: Anemia and its related clinical effects, including dependence on red blood cells (RBC) tra...
We read with great interest the manuscript written by Bayar et al. (1) entitled “Assessment of the relationship between fragmented QRS and cardiac iron overload in patients with beta-thalassemia major,” published in the February 2015 issue of the Anatolian Journal of Cardiology. In that study, they investigated the relationship between fragmented QRS (fQRS), which is a marker of depolarization ...
Introduction About the 11-14% of patients with thalassemia major (TM) treated with deferasirox (DFO) develops retinopathy and/or lens opacities with an unclear pathogenesis but with a clear age related pattern. Possible causes can be either iron overload itself or DFO toxicity, with various mechanisms. No ocular side effects related to L1 are described. During the core study referring to one ye...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید